Quantcast

Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed

June 20, 2013

The Firm is investigating Byetta lawsuits on behalf of type 2 diabetics who developed pancreatic cancer, pancreatitis, or thyroid cancer, allegedly due to Byetta.

New York, New York (PRWEB) June 20, 2013

Byetta pancreatic cancer lawsuit filings continue to mount in courts around the country, Bernstein Liebhard LLP notes that a new investigation by the British Medical Journal (BMJ) has concluded that the pancreatic risks associated with incretin mimetics like Byetta may have been downplayed by the drugs´ manufacturers. According to a report from MedPageToday.com, the BMJ investigation consisted of a review of regulatory documents that discovered unpublished data pointing to “unwanted proliferative or inflammatory pancreatic effects” associated with incretin mimetics. The authors of the report also faulted the U.S. Food & Drug Administration (FDA) and European regulators for failing to aggressively address these concerns.*

“This report just confirms that links between Byetta and pancreatic cancer, as well as pancreatitis, need further review,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta pancreatic cancer lawsuit evaluations to patients who took this drug and were later diagnosed with the disease. Bernstein Liebhard LLP is also investigating claims related to Byetta pancreatitis and thyroid cancer.

Byetta Pancreatic Cancer Lawsuits

Court documents indicate that dozens of Byetta lawsuits have been filed by plaintiffs who suffered pancreatitis and pancreatic cancer, allegedly due to their use of the drug. The U.S. Judicial Panel on Multidistrict Litigation (JPML) will meet on July 25th to hear Oral Arguments regarding the proposed consolidation of all federally-filed personal injury lawsuits involving Byetta and other incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Concern´s about Byetta´s effects on the pancreas have been mounting since 2008, when the FDA reported that Byetta had been associated with a high number of adverse event reports involving pancreatitis.** In February 2011, research published in Gastroenterology linked the drug to a nearly three-fold increase in the risk for pancreatic cancer, and a six-fold increase in the risk for pancreatitis.*** The same study also reported 30 cases of Byetta thyroid cancer in patients taking the drug. On March 14, 2013, the FDA announced it was investigating findings from an unpublished study that suggested incretin mimetics like Byetta could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.****

On June 10, the American Diabetes Association called for an independent review of Byetta and other incretin mimetics due to the recent controversy. Among other things, the group is requesting that the manufacturers of these medications make patient-level data available on all subjects involved in regulatory trials for such an analysis.*****

Alleged victims of Byetta pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills and other damages. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP´s website. To arrange for a free case review, please call 800-511-5092.

*medpagetoday.com/Endocrinology/Diabetes/39803, MedPageToday, June 10, 2013

**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm; FDA, August 18, 2008

***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011

****diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html, ADA, June 10, 2013

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.byettalawsuit2013.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebbyetta-lawsuit/byetta-pancreatic-cancer/prweb10854869.htm


Source: prweb



comments powered by Disqus